NASDAQ:BVS
Bioventus Inc.
Bioventus Inc.'s revenue fell 0.9% in fiscal 2025 to $568.1M while operating margin rose to 9.5%, its highest in 7 years. Free cash flow was $72.1M, 12.7% of revenue, and the diluted share count rose 6.8%.Summary generated from Bioventus Inc.'s SEC filings. Latest annual report filed Mar 5, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$568.1M
Revenue growth−0.9%
Revenue, 5-yr CAGR+12.1%
Gross margin68.3%
Operating margin9.5%
Net margin4.0%
ROIC12.4%
Return on equity13.7%
Debt / equity1.60
Free cash flow$72.1M
FCF margin12.7%
Share count change+6.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 431 | 512 | 512 | 573 | 568 |
| Operating income | 12 | −167 | −82 | −15 | 54 |
| Net income | 19 | −159 | −156 | −36 | 23 |
| Free cash flow | 9 | −15 | 8 | 38 | 72 |
Recent filings
- 10-QQuarterly report for the period ended Jun 27, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 4Insider transaction report
Jun 4, 2026 - 4Insider transaction report
Jun 4, 2026 - 8-KResults of a shareholder vote
Jun 4, 2026 - 8-KRegulation FD disclosure
May 21, 2026 - 10-QQuarterly report for the period ended Mar 28, 2026
May 6, 2026 - 8-KResults of operations and financial condition
May 6, 2026